Technologies du CNRS

Trouvez les meilleures technologies du CNRS pour mener à bien votre projet d’innovation.

Les brevets les plus récents

Vous êtes un chercheur ?

Nous pouvons vous accompagner sur toute votre
démarche de transfert de technologies.

Voir tous nos services

Vous êtes un industriel ?

Grâce à notre expérience, nos réseaux et notre connaissance de l’écosystème de l’innovation nous vous accompagnons tout au long de votre projet.

Nous contacter

Découvrez les technologies du CNRS

Voir nos actualités et rendez-vous

Rencontrez l’équipe

Fermer

Adenoviral coat protein delivery vehicles for use as a vaccine platform

Référence

09073-01

Statut des brevets

European priority patent application filed on March the 31st , 2016 and entitled “Adenoviral coat protein derived delivery vehicles technical field of the invention”

Inventeurs

Pascal FENDER
Imre BERGER
Frédéric GARZONI

Statut commercial

Exclusive or non-exclusive license

Laboratoire

Institut de Biologie Structurale (IBS) Grenoble, France

Description

CONTEXT

Infectious diseases continue to plague and decimate populations world-wide. Among the means at our disposal to counter this threat, vaccination has proven to be exceptionally powerful. Nonetheless, severe threats continue to challenge human health, notably also from emergent viruses that have adapted and emerged as new diseases. Recent such examples are the severe threat posed by Chikungunya and Zika insect-born viruses. Ideally, a vaccine will be safe, non-replicative, efficient, and tunable with the possibility to be produced easily at industrial scale.

TECHNICAL DESCRIPTION

The present invention relates to new adenoviral coat protein based delivery vehicles. They are based on a modified penton base protomers that assemble into VLPs. Exposed areas of the penton base proteins can be modified to allow the VLP to specifically bind to any target and/or to comprise any desired peptide epitope.

DEVELOPMENT STAGE

Available vaccine particle: displaying Chikungunya epitope
In vivo (mice) PoC

BENEFITS

Rapid production
Strong immune response
Safe
Optimized antigen presentation

INDUSTRIAL APPLICATIONS

The objective is to generate a pipeline in different domains: infectious diseases, veterinary applications, therapeutic vaccines in oncology. The developments could be conducted in the frame of a start-up.

For further information, please contact us (Ref 09073-01)

Besoin de plus d'informations ?

Nous contacter
Fermer

Contactez-nous

  • Ce champ n’est utilisé qu’à des fins de validation et devrait rester inchangé.
Fermer

Les brevets les plus récents